Diagnostic biomarkers in venous thromboembolic disease

被引:22
作者
Jacobs, Benjamin [1 ]
Obi, Andrea [1 ]
Wakefield, Thomas [1 ]
机构
[1] Univ Michigan, Dept Surg, Vasc Surg Sect, Ann Arbor, MI 48109 USA
关键词
DEEP-VEIN THROMBOSIS; SOLUBLE P-SELECTIN; C-REACTIVE PROTEIN; D-DIMER TEST; ADHESION MOLECULES; CANCER-PATIENTS; VIENNA CANCER; PLASMA-LEVELS; TISSUE FACTOR; PULMONARY-EMBOLISM;
D O I
10.1016/j.jvsv.2016.02.005
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Venous thromboembolism (VTE) is a common disease with serious, often fatal sequelae. The optimal strategy for diagnosis of VTE remains unclear, although considerable progress has been made in this area. Several new biomarkers have showed promise for diagnosis of VTE, and more are under active investigation. We reviewed the literature for studies evaluating these diagnostic biomarkers. Methods: We reviewed the English literature between 1990 and 2015, searching for papers evaluating diagnostic performance of biomarkers in VTE. Results: D-dimer, a fibrin degradation product, has been thoroughly investigated, and performs well in select populations, although it is best as a rule-out test because of its generally low specificity. Soluble P-selectin, a marker of endothelial activation, has shown good diagnostic performance in several studies but has not yet been adopted widely. Others, including cellular adhesion molecules, tissue factor, circulating microparticles, and C-reactive protein, are under investigation, with varying results in a few studies. Conclusions: At this time, D-dimer and P-selectin remain the most clinically valuable. New biomarkers are needed for clinical use in VTE.
引用
收藏
页码:508 / 517
页数:10
相关论文
共 50 条
  • [31] Maternal death by venous thromboembolic disease
    Rossignol, M.
    Morau, E.
    Dreyfus, M.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2017, 45 (12): : S31 - S37
  • [32] Maternal death by venous thromboembolic disease
    Rossignol, M.
    Morau, E.
    Dreyfus, M.
    ANESTHESIE & REANIMATION, 2018, 4 (01): : 47 - 55
  • [33] Usefulness of blood biomarkers for predicting venous thromboembolism in Japanese patients with cancer
    Harada, Yohei
    Sato, Akemi
    Nishioka, Atsujiro
    Ogusu, Shinsuke
    Matsumoto, Masanori
    Sueoka, Eisaburo
    Kawaguchi, Atsushi
    Kimura, Shinya
    Sueoka-Aragane, Naoko
    ONCOLOGY LETTERS, 2023, 25 (05)
  • [34] Venous thromboembolic disease and air travel
    Sanchez, O.
    REVUE DE MEDECINE INTERNE, 2008, 29 (06): : 445 - 448
  • [35] Optimal duration of anticoagulant treatment after venous thromboembolic disease
    Tromeur, Cecile
    Couturaud, Francis
    PRESSE MEDICALE, 2015, 44 (7-8): : 779 - 790
  • [36] Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population
    Kishore, Sirish A.
    Bajwa, Raazi
    Van Doren, Layla
    Wilkins, Cy
    O'Sullivan, Gerard J.
    CURRENT ONCOLOGY REPORTS, 2022, 24 (03) : 351 - 362
  • [37] Lung cancer associated venous thromboembolic disease: A comprehensive review
    Corrales-Rodriguez, Luis
    Blais, Normand
    LUNG CANCER, 2012, 75 (01) : 1 - 8
  • [38] Recurrence risk in venous thromboembolic disease after anticoagulation discontinuation
    Calvo Romero, Jose Maria
    MEDICINA CLINICA, 2013, 140 (07): : 310 - 313
  • [39] Multiple markers of hypercoagulation in patients with history of venous thromboembolic disease
    Bern, Murray
    McCarthy, Nancy
    BLOOD COAGULATION & FIBRINOLYSIS, 2013, 24 (01) : 59 - 63
  • [40] The venous thromboembolic disease among cancer patients: physiopathology and therapeutic
    Maleb, Adil
    Messaoudi, Nezha
    SANG THROMBOSE VAISSEAUX, 2011, 23 (01): : 34 - 40